These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity

1 hour ago 2

Trey Thoelcke

Thu, March 19, 2026 astatine 8:10 AM CDT 6 min read

Bristol Myers Squibb (BMY) reported Q4 2025 non-GAAP EPS of $1.26, missing statement by 22.7% owed to a $1.39B acquired IPRD charge, portion bequest drugs Revlimid and Sprycel fell 55% and 60% respectively with generic pomalidomide introduction expected successful Q1 2026. FedEx (FDX) bushed Q2 FY2026 adjusted EPS estimates by implicit 17% astatine $4.82 with a planned Freight spin-off targeted for June 1, 2026, and raised full-year guidance to $17.80-$19.00 adjusted EPS. Ralph Lauren (RL) delivered Q4 gross of $2.406B beating estimates by 4.16% with EPS of $6.22 topping expectations by 7.10%, positive 22.4% Asia gross maturation with China up implicit 30% for the 2nd consecutive quarter.
A decease transverse method awesome has formed for each 3 stocks, but Bristol Myers Squibb faces genuine cardinal headwinds from bequest cause obsolescence and pipeline binary risks, portion FedEx and Ralph Lauren amusement beardown caller net beats and affirmative guidance contempt the method breakdown reflecting broader marketplace volatility alternatively than company-specific deterioration.
A caller survey identified 1 azygous wont that doubled Americans’ status savings and moved status from dream, to reality. Read much here.

A decease transverse forms erstwhile a stock's 50-day moving mean crosses beneath its 200-day moving average, signaling a imaginable downtrend. Right now, Bristol Myers Squibb (NYSE: BMY), FedEx (NYSE: FDX), and Ralph Lauren (NYSE: RL) are each flashing that signal. With the CBOE Volatility Index (VIX) astatine astir 25, elevated macro uncertainty is clustering these method breakdowns crossed sectors. But the awesome does not transportation adjacent value for each three. Here is however they rank, from astir technically justified to slightest technically justified.

Bristol Myers Squibb, oregon BMS, presents the weakest cardinal lawsuit for ignoring the bearish signal. The banal is up 10% year-to-date and trades astir $59.30, but the guardant representation is discouraging. An AI terms exemplary projects $55.60 with a Hold recommendation, implying astir 6.4% downside from existent levels. Analyst statement is modestly much optimistic astatine $62.72, but adjacent that leaves constricted upside comparative to the risks.

The astir caller 4th told a analyzable story. Q4 2025 non-GAAP EPS came successful astatine $1.26, missing the $1.63 statement by 22.7%, mostly driven by a $1.39 cardinal acquired IPRD complaint tied to the Orbital Therapeutics acquisition. Revenue of $12.5 cardinal bushed estimates slightly, but full-year 2025 gross declined 0.22% year-over-year. Legacy drugs are successful freefall: Revlimid fell 55% and Sprycel by 60% successful Q4, with generic pomalidomide introduction expected successful Q1 2026. Management's 2026 gross guidance of $46.0 cardinal to $47.5 cardinal implies a measurement down from 2025 actuals. The pipeline is genuinely rich, with FDA precedence reappraisal decisions for iberdomide expected by August 2026 and Opdivo successful Hodgkin Lymphoma owed April 8, 2026, but binary catalysts adhd risk, not certainty. The decease transverse present reflects a institution successful a existent transitional squeeze.

Read Entire Article